Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid Tumors

Next Previous
Search
Trial Profile

Phase I/II Study of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma, and Other GD2(+) Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivatrotamab (Primary)
  • Indications Histiocytoma; Leiomyosarcoma; Liposarcoma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Osteosarcoma; Retinoblastoma; Sarcoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Y-mAbs Therapeutics

    • Most Recent Events

    • 11 Jul 2022 Status changed from recruiting to discontinued.
    • 16 Dec 2020 According to a Y-mAbs Therapeutics media release, the company will present an update for this study, covering the first six cohorts of the study.
    • 07 Oct 2020 According to a Y-mAbs Therapeutics media release, the company plans to expand this phase II study into two separate Phase 2 arms in neuroblastoma and osteosarcoma, respectively.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top